Rhumbline Advisers Passage Bio, Inc. Transaction History

Rhumbline Advisers

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$0.82 - $1.19 $642 - $931	783 New	783 $0
Q2 2022 Aug 11, 2022	SELL	$1.63 - $3.46 $75,889 - $161,090	-46,558 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$2.66 - $6.49 $2,697 - $6,580	-1,014 Reduced 2.13%	46,558 $144,000
Q4 2021 Feb 10, 2022	BUY	$6.24 - $10.2 $2,970 - $4,855	476 Added 1.01%	47,572 $302,000
Q3 2021 Nov 12, 2021	BUY	$9.73 - $15.52 $16,784 - $26,772	1,725 Added 3.8%	47,096 $469,000
Q2 2021 Aug 05, 2021	BUY	$12.44 - $19.45 $200,906 - $314,117	16,150 Added 55.27%	45,371 $601,000
Q1 2021 May 06, 2021	BUY	$16.24 - $29.83 $29,296 - $53,813	1,804 Added 6.58%	29,221 $511,000
Q4 2020 Feb 10, 2021	BUY	$14.28 - $29.73 $161,835 - $336,930	11,333 Added 70.46%	27,417 $701,000
Q3 2020 Nov 12, 2020	SELL	$12.39 - $26.15 $31,098 - $65,636	-2,510 Reduced 13.5%	16,084 $211,000
Q2 2020 Aug 13, 2020	BUY	$14.59 - $36.07 $271,286 - $670,685	18,594 New	18,594 $508,000

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.9M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.